Testosterone and Cardiovascular Disease

Journal of the American College of Cardiology

Volumn 67, Issue 5, 2016, Pages 545-557

  Kloner, Robert A ^a,b   Carson, Culley ^c   Dobs, Adrian ^d   Kopecky, Stephen ^e   Mohler, Emile R ^f  

^a HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

angina; heart failure; hormone replacement therapy; major adverse cardiovascular events; male health; myocardial infarction

Indexed keywords

TESTOSTERONE; ANDROGEN;

AGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL RESEARCH; DISEASE ASSOCIATION; DRUG INDICATION; DRUG LABELING; DRUG RESPONSE; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LABORATORY DIAGNOSIS; PRIORITY JOURNAL; REVIEW; SYMPTOM; SYSTOLIC HEART FAILURE; TESTOSTERONE BLOOD LEVEL; VEIN THROMBOSIS; AGED; CARDIOVASCULAR DISEASES; MALE; METABOLISM; PHYSIOLOGY; RISK FACTOR;

AGED; AGING; ANDROGENS; CARDIOVASCULAR DISEASES; HUMANS; HYPOGONADISM; MALE; RISK FACTORS; TESTOSTERONE;

EID: 84973449706     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.12.005     Document Type: Review

References (121)

1. 1 Mooradian, A.D., Morley, J.E., Korenman, S.G., Biological actions of androgens. Endocr Rev 8 (1987), 1–28.
2. 2 Walsh, J.P., Kitchens, A.C., Testosterone therapy and cardiovascular risk. Trends Cardiovasc Med 25 (2015), 250–257.
3. 3 Bhasin, S., Cunningham, G.R., Hayes, F.J., et al., Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95 (2010), 2536–2559.
4. 4 Khera, M., Bhattacharya, R.K., Blick, G., et al. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med 8 (2011), 3204–3213.
5. 5 Cunningham, G.R., Stephens-Shields, A.J., Rosen, R.C., et al. Association of sex hormones with sexual function, vitality, and physical function of symptomatic older men with low testosterone levels at baseline in the testosterone trials. J Clin Endocrinol Metab 100 (2015), 1146–1155.
6. 6 Zitzmann, M., Mattern, A., Hanisch, J., et al. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 10 (2013), 579–588.
7. 7 Knapp, P.E., Storer, T.W., Herbst, K.L., et al. Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss. Am J Physiol Endocrinol Metab 294 (2008), E1135–E1143.
8. 8 Travison, T.G., Basaria, S., Storer, T.W., et al. Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci 66 (2011), 1090–1099.
9. 9 Wu, F.C., Tajar, A., Pye, S.R., et al., for the European Male Aging Study Group. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 93 (2008), 2737–2745.
10. 10 Iglesias, P., Prado, F., Macías, M.C., et al. Hypogonadism in aged hospitalized male patients: prevalence and clinical outcome. J Endocrinol Invest 37 (2014), 135–141.
11. 11 Langouche, L., Van den Berghe, G., Hypothalamic-pituitary hormones during critical illness: a dynamic neuroendocrine response. Handb Clin Neurol 124 (2014), 115–126.
12. 12 Dhindsa, S., Reddy, A., Karam, J.S., et al. Prevalence of subnormal testosterone concentrations in men with type 2 diabetes and chronic kidney disease. Eur J Endocrinol 173 (2015), 359–366.
13. 13 Sumii, K., Miyake, H., Enatsu, N., Matsushita, K., Fujisawa, M., Prospective assessment of health-related quality of life in men with late-onset hypogonadism who received testosterone replacement therapy. Andrologia, 2015 May 18 [E-pub ahead of print].
14. 14 Harman, S.M., Metter, E.J., Tobin, J.D., et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 86 (2001), 724–731.
15. 15 Araujo, A.B., Dixon, J.M., Suarez, E.A., et al. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 96 (2011), 3007–3019.
16. 16 Corona, G., Rastrelli, G., Monami, M., et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 165 (2011), 687–701.
17. 17 Ruige, J.B., Mahmoud, A.M., De Bacquer, D., et al. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 97 (2011), 870–875.
18. 18 Hak, A.E., Witteman, J.C., de Jong, F.H., et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrin Metal 87 (2002), 3632–3639.
19. 19 Rosano, G.M., Sheiban, I., Massaro, R., et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res 19 (2007), 176–182.
20. 20 Ohlsson, C., Barrett-Connor, E., Bhasin, S., et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol 58 (2011), 1674–1681.
21. 21 Hu, X., Rui, L., Zhu, T., et al. Low testosterone level in middle-aged male patients with coronary artery disease. Eur J Intern Med 22 (2011), e133–e136.
22. 22 Li, L., Guo, C.Y., Jia, E.Z., et al. Testosterone is negatively associated with the severity of coronary atherosclerosis in men. Asian J Androl 14 (2012), 875–878.
23. 23 Alkamel, A., Shafiee, A., Jalali, A., et al. The association between premature coronary artery disease and level of testosterone in young adult males. Arch Iran Med 17 (2014), 545–550.
24. 24 Farias, J.M., Tinetti, M., Khoury, M., et al. Low testosterone concentration and atherosclerosis disease markers in male patients with type 2 diabetes. J Clin Endocrinol Metab 99 (2014), 4698–4703.
25. 25 Lee, W.C., Kim, M.T., Ko, K.T., et al. Relationship between serum testosterone and cardiovascular disease risk determined using the Framingham Risk Score in male patients with sexual dysfunction. World J Mens Health 32 (2014), 139–144.
26. 26 Shores, M.M., Matsumoto, A.M., Testosterone, aging, and survival: biomarker or deficiency. Curr Opin Endocrinol Diabetes Obes 21 (2014), 209–216.
27. 27 Surampudi, P., Swerdloff, R.S., Wang, C., An update on male hypogonadism therapy. Expert Opin Pharmacother 15 (2014), 1247–1264.
28. 28 Golan, R., Scovell, J.M., Ramasamy, R., Age-related testosterone decline is due to waning of both testicular and hypothalamic-pituitary function. Aging Male 18 (2015), 201–204.
29. 29 Wu, F.C., Tajar, A., Beynon, J.M., et al., for the EMAS Group. Identification of late-onset hypogonadism in middle aged and elderly men. N Engl J Med 363 (2010), 123–135.
30. 30 Ahmadi, H., Daneshmand, S., Androgen deprivation therapy: evidence-based management of side effects. BJU Int 111 (2013), 543–548.
31. 31 Girard, D., Marino, F.E., Cannon, J., Evidence for reduced neuromuscular function in men with a history of androgen deprivation therapy for prostate cancer. Clin Physiol Funct Imaging 34 (2014), 209–217.
32. 32 Storer, T.W., Miciek, R., Travison, T.G., Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J Androl 14 (2012), 204–221.
33. 33 Kwan, M., Greenleaf, W.J., Mann, J., et al. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab 57 (1983), 557–562.
34. 34 Lee, K.K., Berman, N., Alexander, G.M., et al. A simple self-report diary for assessing psychosexual function in hypogonadal men. J Androl 24 (2003), 688–698.
35. 35 Chiang, H.S., Cho, S.L., Lin, Y.C., et al. Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Urology 73 (2009), 762–766.
36. 36 Tajar, A., Huhtaniemi, I.T., O'Neill, T.W., et al., for the EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab 97 (2012), 1508–1516.
37. 37 Corona, G., Isidori, A.M., Buvat, J., et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med 11 (2014), 1577–1592.
38. 38 Guay, A.T., Bansal, S., Heatley, G.J., Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab 80 (1995), 3546–3552.
39. 39 Bhattacharya, R.K., Khera, M., Blick, G., et al. Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS). BMC Endocr Disord, 11, 2011, 18.
40. 40 Greenstein, A., Mabjeesh, N.J., Sofer, M., et al. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed?. J Urol 173 (2005), 530–532.
41. 41 Shabsigh, R., Kaufman, J.M., Steidle, C., et al. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 172 (2004), 658–663.
42. 42 Cavallini, G., Caracciolo, S., Vitali, G., et al. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 63 (2004), 641–646.
43. 43 Barrett-Connor, E., Von Mühlen, D.G., Kritz-Silverstein, D., Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab 84 (1999), 573–577.
44. 44 Giltay, E.J., Tishova, Y.A., Mskhalaya, G.J., et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med 7 (2010), 2572–2582.
45. 45 Orengo, C.A., Fullerton, L., Kunik, M.E., Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J Geriatr Psychiatry Neurol 18 (2005), 20–24.
46. 46 Alexander, G.M., Swerdloff, R.S., Wang, C., et al. Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Horm Behav 33 (1998), 85–94.
47. 47 Janowsky, J.S., Chavez, B., Orwoll, E., Sex steroids modify working memory. J Cogn Neurosci 12 (2000), 407–414.
48. 48 Emmelot-Vonk, M.H., Verhaar, H.J., Nakhai Pour, H.R., et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 299 (2008), 39–52.
49. 49 Shortridge, E.F., Polzer, P., Donga, P., et al. Experiences and treatment pattern of hypogonadal men in the US health system. Int J Clin Pract 68 (2014), 1257–1263.
50. 50 Shortridge, E.F., Polzer, P., Donga, P., et al. Symptom report and treatment experience of hypogonadal men with and without type 2 diabetes in a United States health plan. Int J Clin Pract 69 (2015), 783–790.
51. 51 Snyder, P.J., Peachey, H., Berlin, J.A., et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85 (2000), 2670–2677.
52. 52 Katznelson, L., Finkelstein, J.S., Schoenfeld, D.A., et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81 (1996), 4358–4365.
53. 53 Snyder, P.J., Peachey, H., Hannoush, P., et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 84 (1999), 2647–2653.
54. 54 Bhasin, S., Calof, O.M., Storer, T.W., et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2 (2006), 146–159.
55. 55 Hildreth, K.L., Barry, D.W., Moreau, K.L., et al. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab 98 (2013), 1891–1900.
56. 56 Basaria, S., Coviello, A.D., Travison, T.G., et al. Adverse events associated with testosterone administration. N Engl J Med 363 (2010), 109–122.
57. 57 Spitzer, M., Huang, G., Basaria, S., et al. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol 9 (2013), 414–424.
58. 58 Rhee, H., Gunter, J.H., Heathcote, P., et al. Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int 115:Suppl 5 (2015), 3–13.
59. 59 Aversa, A., Bruzziches, R., Francomano, D., et al. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. Aging Male 15 (2012), 96–102.
60. 60 Dabaja, A.A., Bryson, C.F., Schlegel, P.N., et al. The effect of hypogonadism and testosterone-enhancing therapy on alkaline phosphatase and bone mineral density. BJU Int 115 (2015), 480–485.
61. 61 Irwig, M.S., Bone health in hypogonadal men. Curr Opin Urol 24 (2014), 608–613.
62. 62 Watts, N.B., Adler, R.A., Bilezikian, J.P., et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97 (2012), 1802–1822.
63. 63 Whitaker, M., Guo, J., Kehoe, T., et al. Bisphosphonates for osteoporosis—where do we go from here?. N Engl J Med 366 (2012), 2048–2051.
64. 64 Laaksonen, D.E., Niskanen, L., Punnonen, K., et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 90 (2005), 712–719.
65. 65 Rolf, C., von Eckardstein, S., Koken, U., et al. Testosterone substitution of hypogonadal men prevents the age-dependent increases in body mass index, body fat and leptin seen in healthy ageing men: results of a cross-sectional study. Eur J Endocrinol 146 (2002), 505–511.
66. 66 Corona, G., Monami, M., Rastrelli, G., et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 34 (2011), 528–540.
67. 67 Cai, X., Tian, Y., Wu, T., et al. Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Asian J Androl 16 (2014), 146–152.
68. 68 Oskui, P.M., French, W.J., Herring, M.J., et al. Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. J Am Heart Assoc, 2, 2013, e000272.
69. 69 Calof, O.M., Singh, A.B., Lee, M.L., et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 60 (2005), 1451–1457.
70. 70 Haddad, R.M., Kennedy, C.C., Caples, S.M., et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 82 (2007), 29–39.
71. 71 Fernández-Balsells, M.M., Murad, M.H., Lane, M., et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systemic review and meta-analysis. J Clin Endocrinol Metab 95 (2010), 2560–2575.
72. 72 Vigen, R., O'Donnell, C.I., Barón, A.E., et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310 (2013), 1829–1836.
73. 73 Traish, A.M., Guay, A.T., Morgentaler, A., Death by testosterone? We think not!. J Sex Med 11 (2014), 624–629.
74. 74 Goldstein, I., Knowledge is power. J Sex Med 11 (2014), 613–615.
75. 75 Hwang, K., Miner, M., Controversies in testosterone replacement therapy: testosterone and cardiovascular disease. Asian J Androl 17 (2015), 187–191.
76. 76 Morgantaler, A., Kacker, R., Testosterone and cardiovascular risk—deciphering the statistics. Nat Rev Urol 11 (2014), 131–132.
77. 77 Kloner, R.A., Testosterone and cardiovascular health: safety of treatment of hypogonadism. Sex Med Rev 3 (2015), 56–62.
78. 78 Morgantaler, A., Lunenfeld, B., Testosterone and cardiovascular risk: world's experts take unprecedented action to correct misinformation. Aging Male 17 (2014), 63–65.
79. 79 Finkle, W.D., Greenland, S., Ridgeway, G.K., et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One, 9, 2014, e85805.
80. 80 Woodcock J. Letter to Sidney Wolfe, M.D. and Michael Carome, M.D., responding to FDA-2014-P-0258, Public Citizen's petition for boxed warning for testosterone-containing drugs. Food and Drug Administration. July 16, 2014. Available at: http://www.citizen.org/documents/2184_FDA Denial of Petition_July 16, 2014.pdf. Accessed December 2, 2015.
81. 81 Layton, J.B., Meier, C.R., Sharpless, J.L., et al. Comparative safety of testosterone dosage forms [published erratum appears in JAMA Intern Med 2015;175:1248]. JAMA Intern Med 175 (2015), 1187–1196.
82. 82 Shores, M.M., Smith, N.L., Forsberg, C.W., et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 97 (2012), 2050–2058.
83. 83 Shores, M.M., Sloan, K.L., Matsumoto, A.M., et al. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry 61 (2004), 162–167.
84. 84 Baillargeon, J., Urban, R.J., Kuo, Y.F., et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother 48 (2014), 1138–1144.
85. 85 Jones, T.H., Arver, S., Behre, H.M., et al., for the TIMES 2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES 2 Study). Diabetes Care 34 (2011), 828–837.
86. 86 Muraleedharan, V., Marsh, H., Kapoor, D., et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 169 (2013), 725–733.
87. 87 Cornoldi, A., Caminiti, G., Marazzi, G., et al. Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. Int J Cardiol 142 (2010), 50–55.
88. 88 Xu, L., Freeman, G., Cowling, B.J., et al. Testosterone therapy and cardiovascular events among men: a systemic review and meta-analysis of placebo-controlled randomized trails. BMC Med, 11, 2013, 108.
89. 89 Corona, G., Maseroli, E., Rastrelli, G., et al. Cardiovascular risk associated with testosterone-boosting medications: a systemic review and meta-analysis. Expert Opinion Drug Saf 13 (2014), 1327–1351.
90. 90 Grech, A., Breck, J., Heidelbaugh, J., Adverse effects of testosterone replacement therapy: an update on the evidence and controversy. Ther Adv Drug Saf 5 (2014), 190–200.
91. 91 Khera, M., Controversies in testosterone supplementation therapy. Asian J Androl 17 (2015), 175–176.
92. 92 Morgentaler, A., Miner, M.M., Caliber, M., et al. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc 90 (2015), 224–251.
93. 93 Sharma, R., Oni, O.A., Gupta, K., et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J 36 (2015), 2706–2715.
94. 94 Snyder, P.J., Ellenberg, S.S., Cunningham, G.R., et al. The Testosterone Trials: seven coordinated trials of testosterone treatment in elderly men. Clin Trials 11 (2014), 362–375.
95. 95 Naghi, J.J., Philip, K.J., DiLibero, D., et al. Testosterone therapy: treatment of metabolic disturbances in heart failure. J Cardiovasc Pharmacol Ther 16 (2011), 14–23.
96. 96 Jankowska, E.A., Biel, B., Majda, J., et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 114 (2006), 1829–1837.
97. 97 Aukrust, P., Ueland, T., Gullestad, L., et al. Testosterone: a novel therapeutic approach in chronic heart failure?. J Am Coll Cardiol 54 (2009), 928–929.
98. 98 Chen, Q., Fu, Z., Wu, X., Association of serum androgen concentrations with cardiovascular risk factors in elderly male patients with chronic systolic heart failure in China. Aging Male 17 (2014), 155–160.
99. 99 Rydlewska, A., Maj, J., Katkowski, B., et al. Circulating testosterone and estradiol, autonomic balance and baroreflex sensitivity in middle-aged and elderly men with heart failure. Aging Male 16 (2013), 58–66.
100. 100 Kaufman, J.M., Vermeulen, A., The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26 (2005), 833–876.
101. 101 Tappler, B., Katz, M., Pituitary-gonadal dysfunction in low output cardiac failure. Clin Endocrinol (Oxf) 10 (1979), 219–226.
102. 102 Jankowska, E.A., Filippatos, G., Ponikowska, B., et al. Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J Card Fail 15 (2009), 442–450.
103. 103 Pugh, P.J., Jones, T.H., Channer, K.S., Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 24 (2003), 909–915.
104. 104 Malkin, C.J., Pugh, P.J., Jones, R.D., et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89 (2004), 3313–3318.
105. 105 Toma, M., McAlister, F.A., Coglianese, E.E., et al. Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail 5 (2012), 315–321.
106. 106 Malkin, C.J., Pugh, P.J., West, J.N., et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 27 (2006), 57–64.
107. 107 Iellamo, F., Volterrani, M., Caminiti, G., et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 56 (2010), 1310–1316.
108. 108 Pugh, P.J., Jones, R.D., West, J.N., et al. Testosterone treatment for men with chronic heart failure. Heart 90 (2004), 446–447.
109. 109 Caminiti, G., Volterrani, M., Iellamo, F., et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 54 (2009), 919–927.
110. 110 Nicolli, G., Milardi, D., D'Amario, D., et al. Hypotestosteronemia is frequent in ST-elevation myocardial infarction patients and is associated with coronary microvascular obstruction. Eur J Prev Cardiol 22 (2015), 855–863.
111. Ca channels via the cGMP-dependent protein kinase. Am J Physiol Heart Circ Physiol 302 (2012), H115–H123.
112. 112 Malkin, C.J., Pugh, P.J., Morris, P.D., et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 90 (2004), 871–876.
113. 113 Mathur, A., Malkin, C., Saeed, B., et al. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol 161 (2009), 443–449.
114. 114 Herring, M.J., Oskui, P.M., Hale, S.L., et al. Testosterone and the cardiovascular system: a comprehensive review of the basic science literature. J Am Heart Assoc, 2, 2013, e000271.
115. 115 Pongkan, W., Chattipakorn, S.C., Chattipakorn, N., Roles of testosterone replacement in cardiac ischemia-reperfusion injury. J Cardiovasc Pharmacol Ther 21 (2016), 27–43.
116. 116 Herring, M.J., Hale, S.L., Shi, J., et al. Supraphysiological testosterone levels shorten the QT interval but do not alter total anatomic myocardial infarct size in rabbits with acute myocardial infarction. Cardiol Pharmacol, 3, 2014, 1.
117. 117 Glueck, C.J., Richardson-Royer, C., Schultz, R., et al. Testosterone therapy, thrombophilia-hypofibrinolysis, and hospitalization for deep venous thrombosis-pulmonary embolus: an exploratory, hypothesis-generating study. Clin Appl Thromb Hemost 20 (2014), 244–249.
118. 118 Baillargeon, J., Urban, R.J., Morgentaler, A., et al. Risk of venous thromboembolism in men receiving testosterone therapy. Mayo Clin Proc 90 (2015), 1038–1045.
119. 119 Bhatt K, Johnson J. Summary Minutes of the Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting, September 18, 2014. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM424069.pdf. Accessed December 2, 2015.
120. 120 FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. U.S. Food and Drug Administration. 2015. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm. Accessed December 2, 2015.
121. 121 Matsumoto, A.M., Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. J Clin Endocrinol Metab 70 (1990), 282–287.